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Hepatic Nuclear Receptor Expression 
Associates with Features of Histology in 
Pediatric Nonalcoholic Fatty Liver Disease
erin e. elbel,1 Joel e. lavine,1 michael Downes,2 mark Van natta,3 Ruth yu,2 Jeffrey B. schwimmer,4 Cynthia Behling,4  
elizabeth m. Brunt,5 James tonascia,3 and Ronald evans2
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adults. This 
study examined the relationship between hepatic nuclear receptor (NR) expression and histologic features of NAFLD. 
Drugs targeting a variety of NRs for nonalcoholic steatohepatitis (NASH) are in clinical trials. Liver messenger RNA was 
isolated from 40 children (10-19 years) undergoing end-of-treatment biopsy in the Treatment of NAFLD in Children 
(TONIC) trial. High-throughput quantitative polymerase chain reaction assayed NR messenger RNA. Cluster analysis was 
used to group 36 NRs, and NR levels were related to histologic measures of specific NAFLD features. Cluster analysis de-
termined five groupings of NRs. Significant (P < 0.05) differential expressions of specific NRs associated with histologic 
measures include farnesoid X receptor alpha and retinoic acid receptor (RARβ and RARβ) for steatosis; estrogen receptor 
alpha (ERα) and peroxisome proliferator-activated receptor gamma 3 (PPARγ3) for hepatocellular ballooning; ER and 
PPARγ2 for lobular inf lammation; PPARα/δ/γ1/γ2, ERα, constitutive androstane receptor, chicken ovalbumin upstream 
promoter transcription factor 1, RARα, RARβ1, retinoid X receptor, pregnane X receptor, thyroid hormone receptors α and 
β, and nuclear receptor related-1 for fibrosis; and ERα and RARβ/β1/α for diagnosis of NASH. Conclusion: Differential ex-
pression of specific NRs correlates with histologic severity of specific NAFLD features. These NRs are pleiotropic transac-
tivators regulating basal metabolic functions and inf lammatory responses. Derangement of activity of these receptors in 
NAFLD provides a rationale for exploiting their ability with receptor-specific ligands to ameliorate NASH and its conse-
quences. (Hepatology Communications 2018;2:1213-1226).
SEE ARTICLE ON PAGE 1157
Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease among preadoles-cents and adolescents in the United States.(1) 
NAFLD encompasses a spectrum of histologic fea-
tures from isolated steatosis (generally nonprogres-
sive) to potentially severe nonalcoholic steatohepatitis 
(NASH).(2) NASH is characterized at the molecular 
level by oxidative stress and activation of proinflamma-
tory profibrotic cascades and is defined histologically 
as steatosis with inflammation and hepatocellular bal-
looning, often accompanied by fibrosis.(3,4) NASH can 
ultimately lead to decompensated cirrhosis or hepato-
cellular carcinoma.(2,5) Among adults, the frequency of 
NASH as an indication for liver transplant increased 
800% between 2001 and 2009 and has become the 
second most common indication overall(6); NASH is 
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RNA; NAFLD, nonalcoholic fatty liver disease; NASH CRN, nonalcoholic steatohepatitis Clinical Research Network; NASH, nonalcoholic 
steatohepatitis; NR, nuclear receptor; NURR1, nuclear receptor related 1; OCA, obeticholic acid; PCR, polymerase chain reaction; PPAR, peroxisome 
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on a trajectory to become the most common indica-
tion for transplant by 2025.(7) In the United States, the 
prevalence of NAFLD among teenagers has doubled 
in the past 20 years and 38% of obese children are 
reported to have NAFLD.(8,9)
Some patients with NAFLD maintain isolated 
hepatic steatosis while others develop inflammation, 
cell injury, and fibrosis (NASH), although the mech-
anisms underlying this spectrum of outcomes are 
unclear.(10,11) The development of NASH is believed 
to involve insulin resistance, lipotoxicity, and the acti-
vation of necro-inflammatory pathways that lead to 
mitochondrial dysfunction and the release of factors 
that trigger apoptosis.(3,12) Attenuation of these steps 
is requisite for improving outcomes.
Nuclear receptors (NRs) are ligand-inducible 
transcription factors that activate hierarchical tran-
scriptional networks. They coordinate multi-organ 
physiologic pathways related to growth, nutrient 
uptake, metabolic homeostasis, and inflammation.(13) 
NRs are expressed in a tissue-dependent, time- 
dependent, and developmentally specific manner, and 
each NR has its own subset of protein targets.(14) NR 
ligands intimately related to NASH pathophysiology 
include fatty acids (both endogenous and dietary), bile 
acids, sex hormones, and vitamins A and D.(15)
In the liver, NRs act as sensors of the metabolic 
milieu, activating transcription of cellular machinery 
for maintenance of homeostasis. NRs act as pleiotropic 
transactivators of transcriptional cascades, coordinat-
ing hepatic functions, including detoxification, storage 
and release of glucose, and production and uptake of 
cholesterol.(16) NRs and their protein targets are inti-
mately involved in pathologic processes underlying the 
metabolic syndrome and NAFLD, including insulin 
resistance, hepatic lipid accumulation and inflamma-
tion, and increased intestinal permeability.(15,17)
Drugs that modulate NR activity, including thiazo-
lidinediones and other peroxisome proliferator-acti-
vated receptor (PPAR) agonists, are widely used in the 
treatment of metabolic disease. Several drugs, includ-
ing obeticholic acid (OCA; a farnesoid X receptor 
[FXR]α agonist), pioglitazone (a PPARγ agonist), and 
elafibranor (GFT505, a dual PPARδ/PPARα agonist) 
have undergone or are undergoing clinical trials in 
humans for the treatment of adult NAFLD and have 
demonstrated variable efficacy.
Despite the accumulating evidence for the role of 
NRs in NASH pathophysiology and treatment, NR 
expression patterns in children with NAFLD have 
not been studied. We hypothesized that NRs would 
be variably expressed in subjects with differing degrees 
of severity as assessed by histology and that NRs with 
therapeutic agonists that are currently undergoing test-
ing (i.e., FXRα, PPARγα/δ, thyroid hormone receptor 
[TR]β) would be most likely to differ with histology. 
The expression pattern of NRs in NAFLD may be a 
useful tool in precision medicine to identify and per-
sonalize treatment of those at particular risk.
Patients and Methods
stuDy population
This ancillary study of the Treatment of NAFLD 
in Children (TONIC) trial had Institutional Review 
Board approval at each of the eight clinical centers 
comprising The National Institute of Diabetes and 
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Digestive and Kidney Diseases-sponsored NASH 
Clinical Research Network (NASH CRN) and 
approval as an ancillary study of the NASH CRN. The 
NR expression participants were obtained only from 
the University of California, San Diego site. Written 
informed consent was obtained from a parent or legal 
guardian, and written assent was obtained from chil-
dren 8-17 years prior to screening and enrollment.
TONIC was a phase IIb, multicenter, double-blind, 
randomized, placebo-controlled trial of either 
taBle 1. pHenotypiC CHaRaCteRiZation oF 40 CHilDRen WitH anD WitHout nasH WitH 
nuCleaR ReCeptoR eXpRession pRoFiles
Not NASH (n = 21) Borderline/Definite NASH (n = 19)
P Value†n Mean (SD) / % n Mean (SD) / %
Demographics
 Female sex 4 19% 3 16% 1.00
 Hispanic ethnicity 16 76% 18 95% 0.19
 Age in years
 Mean (SD) 15.0 (2.4) 14.7 (2.7) 0.72
 Minimum, maximum 11, 19 10, 19
Tanner stage 1.00
 1-3 13 62% 11 65%
 4-5 8 38% 6 35%
Anthropometric
 Body mass index in kg/m2 32.8 (6.4) 33.3 (5.3) 0.80
Histology*
Steatosis score 0.003
 0 = <5% 7 33% 0 0%
 1 = 5%-33% 9 43% 6 32%
 2 = 34%-66% 2 10% 10 53%
 3 = >66% 3 14% 3 16%
Lobular inflammation score <0.001
 0 = 0 2 10% 0 0%
 1 = <2 under 20× 
magnification
19 90% 6 32%
 2 = 2-4 under 20× 
magnification
0 - 9 47%
 3 = >4 under 20× 
magnification
0 - 4 21%
Ballooning score <0.001
 0 = none 18 86% 5 26%
 1 = few 3 14% 6 32%
 2 = many 0 - 8 42%
Fibrosis stage <0.001
 0 = none 10 48% 2 11%
 1a = mild, zone 3 
perisinusoidal
2 10% 2 11%
 1b = moderate, zone 3 
perisinusoidal
0 0% 1 5%
 1c = portal/periportal only 8 38% 2 11%
 2 = zone 3 and periportal 1 5% 8 42%
 3 = bridging 0 0% 4 21%
TONIC treatment 0.05
 Metformin 5 24% 7 37%
 Vitamin E 11 53% 3 16%
 Placebo 5 24% 9 47%
*Biopsies at 96 weeks of treatment were selected for NR expression levels.
†Based on Fisher’s exact test for categorical variables and t test for continuous variables.
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metformin or vitamin E versus placebo in 173 sub-
jects 8-17 years with biopsy-proven NAFLD and per-
sistent alanine aminotransferase >60.(17,18) Exclusion 
criteria for TONIC have been described and include 
diabetes, cirrhosis, use of drugs that could cause or 
treat fatty liver, and bariatric or hepatobiliary surgery. 
The TONIC trial concluded in March 2010. End-of-
treatment percutaneous liver biopsies were obtained 
on enrolled subjects after 96 weeks of oral daily dos-
ing of vitamin E (800 IU/day), metformin (1 g/day), or 
placebo. Flash-frozen fragments of the end-of-treat-
ment biopsies from the last 40 subjects enrolled at the 
University of California, San Diego were prepared for 
profiling for NR expression as described below. The 
liver tissue used in this study consisted of small frag-
ments of the biopsy taken for assessment of histologic 
changes, and a second pass was not made to obtain 
the sample. These 40 subjects had been randomized 
to receive metformin (n = 12), vitamin E (n = 14), or 
placebo (n = 14). Ethnic makeup, body mass index, and 
Tanner staging of the subjects at time of enrollment are 
summarized in Table 1.
HistologiC eValuation
Biopsy specimens were evaluated, scored, and graded 
for histologic features of NAFLD by the Pathology 
Committee of NASH CRN in a centralized con-
sensus review format; they were blinded to all clini-
cal information and used validated criteria by Kleiner 
et al.(18) Specimens were scored for steatosis (grade 0 
[macrovesicular fat in <5% of hepatocytes], grade 1 
[5%-33%], grade 2 [34%-66%], and grade 3 [>66%]), 
lobular inflammation (0-3), ballooning (0-2), and 
fibrosis (stage 0, stage 1a [mild zone 3], stage 1b [mod-
erate zone 3 perisinusoidal], stage 1c [portal/periportal 
fibrosis only], stage 2 [zone 3 and periportal fibrosis], 
stage 3 [bridging fibrosis], and stage 4 [cirrhosis]).
Additionally, pattern-based diagnoses were given 
for each biopsy. The NAFLD pattern of isolated ste-
atosis (“not NASH”) versus “borderline zone 1 pat-
tern” (a pattern more common in pediatric NAFLD), 
“borderline zone 3 pattern,” or “definite NASH” were 
determined according to specific criteria published by 
the committee.(9)
nR pRoFiling
Total liver messenger RNA (mRNA) was isolated 
using the RNAqueous-Micro kit (Life Technologies, 
Grand Island, NY). Complementary DNA (cDNA) 
amplification was performed using the WT-Ovation 
RNA Amplification System (NuGen, San Carlos, 
CA). The cDNA product yield and purity were 
assessed using an Agilent 2100 Bioanalyzer. The Total 
Human Reference RNA was prepared for cDNA 
synthesis. Xpress Reference Human Universal RNA 
(SuperArray/Qiagen, Hilden, Germany) was spiked 
with 1 μL of each NASH CRN sample cDNA and 
used to generate a quantitative polymerase chain reac-
tion (qPCR) standard curve.
Relative NR expression levels were determined by 
high-throughput qPCR. Primers and probes were 
designed using ABI PrimerExpress software. Sequences 
of primers and probes used in this study have been 
reported(19) and were designed to have similar ampli-
fication efficiencies. All probes for TaqMan real-time 
PCR were 5′ labeled with 6-carboxyfluorescein and 
3′ labeled with 6-carboxytetramethylrhodamine. PCR 
reactions were assembled using a Janus automated 
workstation (PerkinElmer, Shelton, CT) contain-
ing 1×TaqMan Universal PCR Master Mix, 300 nM 
primers, 250 nM probe, and cDNA equivalent to 1 ng 
total RNA in a 10-mL volume. PCR was performed in 
an ABI PRISM 7700 detection system (Perkin Elmer) 
at 50C for 2 minutes and 95C for 10 minutes, followed 
by 40 two-step cycles of 95C for 15 seconds and 60C 
for 1 minute. Relative mRNA levels were calculated 
using the comparative delta-Ct method and normal-
ized against separately measured 50S ribosomal protein 
L15 mRNA levels in the same total RNA samples.(20) 
Expression of the 36 NRs known at the time of analy-
sis and that had primer sets validated for amplification 
efficiency criteria was compared among categories of 
steatosis, lobular inflammation, ballooning, and NASH 
diagnosis. The normalized expression level reported for 
each NR represents the number of qPCR cycles neces-
sary to generate detectable fluorescence of the receptor 
in the sample. These units are nonlinear representa-
tions of the amount of base mRNA substrate.
statistiCal analysis
Demographic, anthropometric, and histologic fea-
tures were compared between children with border-
line or definite NASH versus those without NASH 
(Table 1). P values were derived from t tests for con-
tinuous variables or Fisher’s exact test for categorical 
variables.
The outcomes of interest for the current investiga-
tion were the expression profile of 36 hepatic NRs in 
pediatric patients with NAFLD. Exploratory analyses 
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included boxplots of the NRs sorted by the median 
level of normalized mRNA level (Fig. 1).
Cluster analysis was used to assess the expression 
profile of NRs. Groupings of the NRs were determined 
using hierarchical clustering with average linkage based 
on their normalized expression levels.(21) Twelve NRs 
had observations with missing data (eight missing vita-
min D receptor (VDR), seven missing  progesterone 
receptor, eight missing retinoic acid receptor (RAR)
γ, four missing germ cell nuclear factor, one miss-
ing PPARδ, three missing nuclear receptor related 1 
(NURR1), two missing PPARδ2, one missing liver 
X receptor (LXR)β, one missing mineralocorticoid 
receptor, four missing estrogen-related receptor, one 
missing PPARγ1, one missing PPARγ2). Missing data 
were imputed with the median and used for both clus-
ter and regression analyses.
Results of the NR and patient cluster analyses were 
displayed separately as linear dendrograms (Supporting 
Figs. S1 and S2) and simultaneously as a heatmap (Fig. 
2). The Duda-Hart criterion for stopping rules was 
used to determine the number of clusters.
Each of the 36 NRs was compared across the fol-
lowing histologic features: steatosis (grade ≤33% versus 
grade >33%), steatohepatitis (none versus borderline/
definite), fibrosis stage (none/mild versus moderate/
advanced), lobular inflammation (<2 versus 2+ foci), 
and ballooning (none versus few/many). To down-
weight the effect of outliers, medians were used as 
summary statistics and robust linear regression was 
used to derive P values. Logistic regression was used 
to globally test the set of NRs within each cluster as 
predictors of each histologic feature dichotomized into 
higher versus lower severity (Table 2).
Two-sided P values were nominal and not adjusted 
for multiple comparisons. Analyses were performed 
using SAS version 9.3 (SAS Institute, Cary, NC) and 
Stata version 14 (StataCorp, College Station, TX).
Results
suBJeCt CHaRaCteRistiCs anD 
Results oF tRial
All 40 subjects received end-of-treatment research 
biopsies on which histologic analyses and NR expres-
sion were performed. Subject treatments included 
placebo, vitamin E, or metformin. No subject was 
excluded from the analyses or lost to follow-up. In 
total, 85% of subjects were Hispanic with a mean body 
mass index of 33.0 ± 5.8 kg/m2. Although all subjects 
had biopsy-proven NAFLD at the time of TONIC 
enrollment, by the end of treatment, 17.5% (n = 7) had 
fully resolved (<5% steatosis and no other evidence 
Fig. 1. Boxplots of 36 NRs sorted by descending median in 40 children with NAFLD. Boxplots of all 36 NRs illustrate the breadth 
of expression of each receptor. VDR demonstrates the lowest mean expression (higher number of PCR cycles needed to detect), while 
CAR demonstrates the highest. Most receptors had at least one outlier. Abbreviations: err; estrogen-related receptor; gr, glucocorticoid 
receptor; lrh, liver receptor homolog 1; mr, mineralocorticoid receptor; pr; ror, RAR-related orphan receptor alpha; reverb, nuclear 
receptor subfamily 1 group D member 1; shp, small heterodimer partner.
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of NASH). Histologically, 47.5% (n = 19) of subjects 
exhibited zone 1 or 3 borderline NASH or definite 
NASH; of that subset, 63% (n = 16) had zone 3 perisi-
nusoidal and periportal fibrosis or had bridging fibrosis 
(i.e., fibrosis stages 2-3).
nR eXpRession soRteD By 
meDian
Boxplots of the 36 NRs illustrate the summary 
measures (including median and interquartile range) 
of the distribution of expression of each NR for the 40 
patients.
ClusteR analyses anD Heat 
map
Cluster analysis revealed two superfamilies of 
NRs that further divided into five individual clusters. 
Superfamily I NRs consisted of cluster Ia (constitu-
tive androstane receptor [CAR], FXRα, liver receptor 
homolog 1), cluster Ib (chicken ovalbumin upstream 
promoter transcription factor 1 [COUP-TFI], LXRα, 
TR2, small heterodimer partner, nuclear receptor sub-
family 1 group D member 1 [REV-ERBAα], RARα, 
TRα), and cluster Ic (COUP-TFII, RAR-related 
orphan receptor alpha, glucocorticoid receptor, reti-
noid X receptor [RXR]β, pregnane X receptor [PXR], 
RAR-related orphan receptor gamma, RXRα, PPARα, 
TRβ). NR cluster Ia receptors were expressed at the 
lowest level, on average, across the sample. Superfamily 
II NRs consisted of IIa (VDR, germ cell nuclear factor 
[GCNF], progesterone receptor, RARγ, PPARδ, estro-
gen receptor alpha [ERα], LXRβ, PPARδ2, NURR1) 
and IIb (mineralocorticoid receptor, RARβ, estro-
gen-related receptor 1, RARβ1, RARβ2, PPARγ1, 
PPARγ2, PPARγ3). NR cluster IIa receptors were 
expressed at the highest level, on average, across the 
sample. The degree of the relationship between each 
NR is designated on the y axis of the dendrogram 
(shorter branch lengths represent greater similarity 
between the NRs).
Fig. 2. Hierarchical clustering of NR expression levels relative to subject clusters. The normalized mRNA expression levels are 
displayed as a heatmap, organized by the results of the NR cluster analysis (main x axis) and the subject cluster analysis (main y 
axis). NRs cluster into two superfamilies and five individual clusters (Ia: CAR, FXRα, LRH1; Ib: COUP-TF1, LXRα, TR2, REV-
ERBa-α, RARα, TRα; Ic: COUP-TFII, RORα, GR, RXRβ, PXR, ROR, RXRα, PPARα, TR; IIa: VDR, GCNF, PR, RARγ, 
PPARδ, ERα, LXRβ, PPARδ2, NURR1; IIb: MR, RARβ, ERR1, RARβ1, RARβ2, PPARγ1, PPARγ2, PPARγ). Subjects cluster 
into three clusters: cluster I, 30 subjects; cluster II, 8 subjects; cluster III, 2 subjects. For both dendrograms, the y axis represents the L2 
(Euclidean) dissimilarity measure. Abbreviations: ERR, estrogen-related receptor; GR, glucocorticoid receptor; LRH1, liver receptor 
homolog 1; MR, mineralocorticoid receptor; PR; REV-ERBa-α, nuclear receptor subfamily 1 group D member 1; RORα, RAR-related 
orphan receptor alpha; shp, small heterodimer partner.
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Cluster analysis of the aggregate mRNA expression 
profiles for each subject revealed three clusters. Cluster 
I consisted of the majority of the sample (30 subjects). 
Cluster II contained 8 subjects, and cluster III con-
tained 2 subjects. Compared to clusters I and II, subject 
cluster III individuals demonstrated higher expression 
of all NRs, a trend that was especially pronounced 
among NR superfamily II receptors. Cluster II sub-
jects demonstrated a higher expression of NR cluster 
Ic receptors but a markedly lower expression of NR 
cluster superfamily II receptors.
Demographics, histology, and treatment group did 
not significantly differ among the three patient clusters 
(I, II, III) derived from the cluster analysis (data not 
shown).
CompaRison oF nRs By 
HistologiC CHaRaCteRistiCs 
soRteD By tHe DissimilaRity 
measuRe FRom ClusteR 
analysis
Median expression levels of NRs were compared by 
steatosis grade (<33% versus ≥33%), hepatocyte bal-
looning (none versus any), lobular inflammation (none/
Fig. 3. Theoretical model of NR functions in the development of NASH. NR functions (in the presence of their respective ligands) 
are potentially protective against the development of NASH. Drugs targeting the pictured PPARδ, PPARγ, and FXRα receptors are 
in trials for the treatment of NASH and the metabolic syndrome. NR–NR heterodimers and interactions are not pictured. (Figure 3 
was created by Dr. Nikita Consul, Columbia University College of Physicians and Surgeons, 2017). Abbreviations: ER, endoplasmic 
reticulum; ROS, reactive oxygen species.
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mild versus moderate/severe), fibrosis (none versus 
any), and type of NAFLD (not NASH versus NASH). 
In general, differentially expressed NRs exhibited sig-
nificantly higher expression (i.e., required fewer qPCR 
cycles to detect, resulting in a numerically smaller nor-
malized expression level) in pathologic states. The rel-
ative expression levels with comparative P values are 
listed in Table 2.
Three NRs (FXRα, RARβ, and RARβ1), located in 
NR cluster Ia and cluster IIb, were expressed at signifi-
cantly higher levels in the state of increased steatosis. 
Further, steatosis grade was significantly different on a 
global test incorporating a regression of all cluster IIb 
receptors. Steatosis grade did not significantly associ-
ate with any other NRs.
ERα, located in cluster IIa, was expressed at a 
higher level in the state of “any” versus “no” balloon-
ing. PPARγ3, in cluster IIb, however, was expressed at 
a lower level in the state of any versus no ballooning. 
PPARγ3 was the only NR expressed at a lower level in 
a pathologic state.
For lobular inflammation, ERα (cluster IIa) and 
PPARγ2 (cluster IIb) were both expressed at higher 
levels in the state of moderate/severe versus none/mild. 
The global test of cluster Ic NRs was also significantly 
different by inflammation severity.
Comparing NR expression by fibrosis status, 12/36 
(33%) of all NRs assayed were expressed at signifi-
cantly higher levels in “any fibrosis” versus “no fibrosis.” 
These included members from each cluster: the PPARs 
(PPARα, PPARγ1, PPARγ2, and PPARδ), two RAR 
isoforms (RARβ1 and RARα), two endobiotic/xeno-
biotic sensors (CAR and PXR), two TRs (TRα and 
TRβ), and two orphan receptors (COUP-TF1 and 
NURR1). The global test of cluster Ib NRs was sig-
nificantly different by fibrosis status.
Comparing the state of NASH versus not NASH 
overall, the RARs (RARy [cluster 4], RARβ1, RARγ 
[both cluster IIb]) demonstrated higher expression in 
the state of NASH versus not NASH. The global tests 
of cluster Ib and cluster IIa were also significantly dif-
ferent by NASH status.
Discussion
In this study, we stratified 40 pediatric subjects with 
NAFLD (at time of enrollment) by histologic NAFLD 
severity to evaluate the differential expression of 36 
NRs in liver biopsy tissue taken at the end of treat-
ment from a clinical trial. Although expression levels of 
NRs may vary based on sex, age/pubertal status,(22) and 
race/ethnicity, the not NASH and borderline/definite 
NASH samples were roughly balanced with respect to 
these features (Table 1).
The discovery that certain NRs are differentially 
expressed in NASH (versus NAFLD that is not 
NASH) and in more severe histologic states provides a 
mechanistic link between the metabolic derangements 
of NASH and recognized features of liver histology. 
These findings support the ongoing development of 
therapeutic NR ligands and may suggest other unex-
plored therapeutic targets. To our knowledge, no study 
has quantified normalized expression of hepatic NRs 
in pediatric NAFLD/NASH.
Cluster analysis groups genes with similar patterns 
of expression and, in the case of NRs, may suggest the 
presence of shared transcriptional drivers.(13) Cluster 
analysis is an exploratory technique aimed at gener-
ating (rather than testing) hypotheses. Research using 
this tool often reveals clusters of genes of related func-
tionality.(23) Encouragingly, the functions of individual 
NR clusters reported here share significant overlap 
with the “nuclear receptor ring of physiology” clusters 
of Bookout et al.(13)
As predicted based on the known pathophysi-
ology of NAFLD, both cluster I and cluster II con-
tained NRs with expression that correlated with more 
severe histologic features. Overall, receptors in cluster 
II were expressed at higher levels and with more vari-
ability between subjects, suggesting a principal role for 
these NRs in the pathogenesis of pediatric NAFLD. 
Both cluster I and cluster II contained NRs that are 
currently under investigation as drug targets or have 
already been exploited pharmacologically, including 
PPARα/δ/γ and FXRα. Other receptors, such as ERα, 
RARy/α/β/β1, and TRα/β, are not yet established as 
drug targets in NASH but have long been recognized 
as key modulators of liver disease. The functions of 
several NRs known to be protective against the devel-
opment of NASH are shown in Fig. 3. The remaining 
NRs that demonstrated differential expression by his-
tology (CAR, PXR, COUP-TFI, GCNF, NURR1) are 
not well characterized and potentially represent new 
therapeutic targets.
We found that several NRs are expressed at higher 
levels in more severe histologic states. It is possible 
that, as in other biologic systems of negative feedback, 
the presence of an NR ligand (whether endogenous 
or as a pharmaceutical agent) acts as a transcriptional 
repressor of the receptor itself to maintain homeosta-
sis. For example, negative feedback is a key aspect of 
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the well-characterized FXRα/bile acid transcriptional 
cascade.(24) Negative feedback would account for our 
finding that differentially expressed NRs have higher 
expression with more histologically severe disease, i.e., 
the up-regulated receptors may be partially compensat-
ing for reduced levels of circulating endogenous ligand.
FXRα, in cluster Ia, is a key regulator of the gut–
liver–adipose axis and is responsible for initiating sys-
temic responses to the fed state.(16) When activated, 
FXRα induces hundreds of genes throughout the body 
that mediate nutrient acquisition and distribution (e.g., 
fibroblast growth factor 19, PPARα) and inhibit hepatic 
lipogenesis (e.g., sterol regulatory element-binding 
transcription factor 1c).(25) Phase 3 trials of OCA, a 
synthetic FXRα agonist, are underway following the 
recent publication of the Farnesoid X Receptor Ligand 
OCA in NASH Treatment (FLINT) trial, which 
reported that OCA administration improved lobular 
inflammation, steatosis, fibrosis, and steatosis but did 
not affect the diagnosis of NASH.(26) Building on this 
trial, we report an association between higher levels of 
steatosis and higher levels of FXRα but no difference 
in FXRα levels with NASH diagnosis. FXRα directly 
induces PPARα and PPARγ, linking the cluster I and 
cluster II NRs.
The PPARs are the only other NRs with agonists 
undergoing phase 3 trials for treatment of NASH. By 
targeting multiple PPAR isoforms, the drugs currently 
on trial for treatment of adult NASH aim to harness 
the diverse metabolic and anti-inflammatory effects of 
this NR class. For example, elafibranor and pioglita-
zone, each agonists of two PPAR isoforms, are being 
tested for NASH treatment in adults.(27,28) In sum, our 
findings support the current understanding of PPARs 
as not only linchpins in lipid and glucose metabolism 
but also anti-inflammatory and antifibrotic regulators 
and suggest that pharmacologic targeting of all three 
isoforms is likely to be effective in pediatric NASH.
Humans express three largely homologous PPAR 
isoforms (PPARα, PPARδ, and PPARγ), each with 
multiple tissue-dependent subisoforms driven by alter-
native splicing or differential promoters (e.g., PPARγ1, 
PPARγ2, PPARγ3). The PPARs are lipid sensors that 
bind specific fatty acids. Adding to the evidence sup-
porting the distinct but related roles of each PPAR 
isoform, we report that PPARα, PPARδ, and PPARγ 
each cluster with different groups of genes but that 
expression of each isoform is elevated in states of 
increased fibrosis. Our findings contradict Francque 
et al.’s recent report of decreased PPARα expression 
with worsened fibrosis among adults with NASH,(29) 
perhaps suggesting a different mechanism for pediatric 
versus adult NASH or differences between populations 
studied (primarily Hispanic in this study).
The three subisoforms of PPARγ are distributed 
into cluster IIb. In addition to its roles in adipocyte 
development and lipid metabolism, PPARγ is also 
strongly associated with monocytes and other cells of 
the immune system where it exerts a potent anti-in-
flammatory effect by inhibiting production of tumor 
necrosis factor alpha.(30,31) Supporting this role, we 
found higher expression of PPARγ2 associated with 
increased lobular inflammation. Overall, our findings 
of altered PPARγ expression across multiple histologic 
domains suggest that PPARγ plays an important role 
in linking adipocyte and monocyte function and adds 
to the burgeoning evidence connecting NAFLD with 
systemic inflammation.
Finally, PPARδ is ubiquitous throughout nearly 
all tissues. In hepatocytes, it inhibits the expression 
of lipogenic genes (e.g., fatty acid synthase and acetyl 
coenzyme A decarboxylase). Although it was the last 
PPAR for which a synthetic ligand was discovered, its 
increasingly recognized role in preventing insulin resis-
tance, hypertriglycidemia, and immune overactivation 
has led to excitement about its potential as a treatment 
for NASH.(29) Although PPARδ has an important 
metabolic role, its position in cluster II near several 
immunomodulatory NRs suggests its anti-inflamma-
tory properties are also salient.
We also report differential expression of the receptors 
for estrogen, thyroid hormone, and vitamin A, known 
modulators of NASH. Estrogen is an in vitro antifi-
brotic agent, as confirmed by several epidemiologic lines 
of evidence.(32) Given this knowledge, it is not surpris-
ing that ER is increased (and possibly therefore estro-
gen is decreased) in the livers with more ballooning, 
lobular inflammation, fibrosis, and NASH diagnosis. 
RAR, the receptor for vitamin A, drives cellular differ-
entiation and regulates mitochondrial and peroxisome 
oxidation of fatty acids. Animal models support the role 
of the RAR family of transcription factors in NASH; 
transgenic mice expressing a dominant negative RARα 
in hepatocytes are used as an animal model for NASH 
and hepatocellular carcinoma.(33) Thyroid hormone is a 
crucial driver of metabolism; hypothyroidism results in 
insulin resistance and increased circulating low-density 
lipoproteins and triglycerides, factors that predispose to 
the development of NAFLD.(34) Indeed, the prevalence 
of hypothyroidism among adults with NASH is twice 
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that of healthy controls.(35) Consequently, it was not 
surprising that both isoforms of TR localized to clus-
ter I (near several metabolism-related NRs) and that 
higher expression of both TRα and TRβ was associ-
ated with fibrosis. RXRβ, which heterodimerizes with 
RAR, thyroid hormone, and VDR and is therefore at 
the center of many NR pathways, was also found to be 
elevated in states of fibrosis.
In this study, fibrosis was the histologic characteristic 
that was discriminated by the largest number of NRs. 
In addition to the PPARs, ERs, RAR/RXRs, and TRs 
discussed above, CAR, PXR, GCNF, and COUP-TF1 
and NURR1 were also found to be expressed at sig-
nificantly higher levels in the setting of any versus no 
fibrosis. Because fibrosis is the only histologic fea-
ture that associates with long-term outcomes of adult 
NAFLD patients,(36) therapeutic modulation of these 
receptors may have important clinical implications.
Finally, we found higher NURR1, GCNF, and 
COUP-TF1 expression in the setting of fibrosis. The 
natural ligands of these orphan receptors are unknown, 
and their role in NAFLD remains similarly unde-
scribed. COUP-TF1 is at the center of several com-
plex cross-regulatory circuits of NRs, including FXRα, 
RXR, and PPARγ, during liver development and pos-
sibly beyond.(37) Understanding crosstalk between the 
NR pathways described above will necessitate a more 
complete characterization of NURR1 and COUP-TF1 
and may lead to clinically meaningful discoveries.
The intricate regulation of NRs accounts for their 
exquisite ability to sense and respond to dynamic 
hormonal and nutritional cues across multiple organ 
systems in a coordinated fashion. However, their pleio-
tropic nature also increases the challenge of designing 
and using NR modulators for therapy. As an illustration 
of this challenge, recent clinical trials of NR agonists 
in biopsy-proven NASH (i.e., FLINT; Pioglitazone, 
Vitamin E, or Placebo for Nonalcoholic Steatohepatitis 
[PIVENS]; and GOLDEN-505) demonstrated para-
doxical and unexpected decoupling of histologic fea-
tures (including steatosis, inflammation, and fibrosis) 
and metabolic effects (including insulin resistance, dys-
lipidemia, and weight gain).(38)
This study is the first to quantify hepatic NR 
expression in a cohort of children with NAFLD, a 
population at greatest risk for poor long-term out-
comes. Strengths of this study include the novelty of 
the population, consensus and blinded review of liver 
biopsies by NASH CRN pathologists, and the range 
of histologic severity in the subject biopsies. The use 
of cluster analysis is also novel. This tool is not only an 
emerging methodology in systems biology (itself a key 
framework for understanding the overarching network 
of the NR superfamily) but could lead to the identifi-
cation of subtypes of NAFLD that respond differently 
to therapeutic interventions.
Limitations of this study include the subject sample 
size and the inherent restrictions of liver biopsy. Liver 
biopsy represents a sample of mixed cell populations. 
NR profile variability may thus represent variability 
between cell types rather than reflecting true patho-
logic differences.(39) Additionally, this study charac-
terized the NR expression in liver tissue while many 
NRs are enriched in and exert their primary effects in 
other tissues. Because this study aimed to characterize 
the expression profiles of all known hepatic NRs in a 
discovery cohort, P <0.05 is liberal given the multiple 
comparisons and should be taken in the context of 
the multiple NR comparisons evaluated. The prelim-
inary findings of this paper should thus be evaluated 
in prospective future studies that can also quantify the 
expression of NR target genes.
Most importantly, the sample size excluded the abil-
ity to analyze by treatment group, with potential obfus-
cation of effects related to treatment effects of vitamin 
E or metformin. Because vitamin E has been reported 
to activate PXR(40) and metformin has been reported 
to affect the expression of several other NRs, including 
CAR, small heterodimer partner, and TR4,(41) the use 
of end-of-treatment biopsies represents a major limita-
tion of this study; thus, these preliminary results should 
be interpreted with caution. Finally, the study reports 
on the histology and NR profiles of posttreatment 
biopsies, although it is possible that treatment itself 
altered NR profiles compared to untreated individuals 
with the same histology.
The association of differential NR expression pat-
terns with pediatric NAFLD of varying histologic 
severity is a novel finding. NRs are the transcriptional 
key at the center of the gut–liver–adipose axis. Their 
integrated actions coordinate metabolism, immune 
function, and cellular activation and differentiation, 
processes that become dysregulated in NAFLD and 
NASH. NRs found to be variably expressed in this 
study correspond to previously recognized therapeu-
tic targets of drugs for NAFLD and the metabolic 
syndrome that are being investigated in preclinical 
development through phase 3 trials. Ongoing efforts 
to identify the ligands for remaining orphan receptors 
and the development of ligands that specifically target 
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hepatic or adipose NRs show promise in the treatment 
of NASH.
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